RNA Jan 2025 16.000 call
- PR Newswire
Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001)
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1).
- Insider Monkey
Is Avidity Biosciences, Inc. (RNA) the Best Performing Long Term Stock in 2024?
We recently published a list of the 7 Best Performing Long Term Stocks in 2024. In this article, we are going to take a look at where Avidity Biosciences, Inc. (NASDAQ:RNA) stands against the other best performing long term stocks in 2024. After the latest 50 basis point rate cut by the Federal Reserve, the […]
- Insider Monkey
Is Avidity Biosciences Inc. (RNA) the Best Performing Small-Cap Stock in 2024?
We recently compiled a list of the 10 Best Performing Small-Cap Stocks in 2024. In this article, we will look at where Avidity Biosciences Inc. (NASDAQ:RNA) ranks among the best-performing small-cap stocks in 2024. The Case for Small Caps The recent Fed rate cut has made the market cautiously optimistic. Despite the unusual timing, historical […]
